Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 79,600 shares, an increase of 907.6% from the April 30th total of 7,900 shares. Based on an average daily trading volume, of 90,300 shares, the days-to-cover […]
Maxim Group reissued their hold rating on shares of Virpax Pharmaceuticals (NASDAQ:VRPX – Free Report) in a research note released on Wednesday morning, Marketbeat.com reports. Virpax Pharmaceuticals Stock Performance VRPX stock opened at $0.72 on Wednesday. Virpax Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $11.77. The business’s 50 day moving […]
Maxim Group reiterated their hold rating on shares of Virpax Pharmaceuticals (NASDAQ:VRPX – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. Virpax Pharmaceuticals Price Performance Shares of VRPX opened at $0.72 on Wednesday. The business’s 50 day simple moving average is $2.96 and its 200-day simple moving average is […]
Shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Free Report) are going to reverse split before the market opens on Friday, March 1st. The 1-10 reverse split was announced on Friday, March 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, March 1st. Virpax Pharmaceuticals Price Performance Shares […]
Virpax Pharmaceuticals (NASDAQ:VRPX – Get Free Report) and Verve Therapeutics (NASDAQ:VERV – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Volatility & Risk Virpax Pharmaceuticals has a […]